









S126New Approaches for Improving Engraftment after Cord
Blood Transplantation
Vanderson Rocha, Hal E BroxmeyerUseof unrelated umbilical cord blood cells (UCB) as an alternative sourceof hematopoietic cell transplantation
(HCT) has beenwidely usedmainly for patients lacking anHLA-matched donor. There aremany advantages for
using CB cells over bone marrow or mobilized peripheral blood (MBP) from volunteer donors, such as rapid
availability, absence of risk for the donor, or decreased incidence of acute graft-versus-host disease (aGVHD).
However, a significant clinical problem is delayed engraftment, which is directly correlated with the number of
hematopoietic stem cells (HSCs) in aCBunit. The understanding ofmethods to improve collection, expansion,
and homing of CB cells, the identification of prognostic factors associated with engraftment that can be easily
modified (eg, strategies for donor choice), and development of new approaches including use of multiple do-
nors, cotransplantation with accessory cells are of crucial importance to circumvent the problem of delayed
engraftment after UCB transplantation. Those approaches may greatly increase the quality and availability of
CB for transplantation.
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transplantationINTRODUCTION
Umbilical cord blood (UCB) transplantation has
extended the availability of allogeneic hematopoietic
cell transplantation (HCT) to patients who would oth-
erwise not be eligible for this curative approach. Prog-
ress in the field of UCB transplantation parallels the
expanding interest in establishing and developing CB
banks worldwide. Today, more than 450,000 CB grafts
are available in more than 50 CB banks, and it is esti-
mated that more than 20,000 UCB transplantations
have been performed worldwide. Currently more than
2000 transplants are being performed yearly around
the world (World Marrow Donor Association
[WMDA] oral communication, March 2009). In com-
parisonwith other sources of allogeneicHCT,UCBof-
fers substantial logistic and clinical advantages [1].
However, the main problem with using UCB for trans-
plantation is the relatively lownumberof hematopoietic
progenitor cells (HPC) and hematopoietic stem cells
(HSC) in UCB compared with bone marrow (BM) orUniversite de Paris 7, Hospital Saint Louis, Paris, France.
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lates into increased risk of graft failure, delayed hemato-
poietic engraftment [2-6], and delayed immune
reconstitution [7,8]. The cumulative incidence of non-
engraftment after UCB transplantation varies from
10% to 20% and the median time to neutrophil
recovery varies from22 to 27 days.Death frequently oc-
curs during aplasia because of opportunistic infections
without any sign of engraftment. However, despite
this acute problem, long-term outcomes of survival
and disease-free survival (DFS) after UCB transplanta-
tion are comparable to other sources of HCT because
the incidence of graft-versus-host disease (GVHD) is
reduced [2-6].
A number of biological factors, including the num-
ber and/or immaturity of HSC or HPC, limited num-
ber of accessory cells for engraftment (lymphocytes
subsets or mesenchymal cells), and homing capacity,
may be involved as mechanisms to explain this delayed
engraftment.
Many approaches have been investigated to en-
hance collection of HSC and HPC in CB units
(CBUs) and to improve homing of CB cells. Examples
include blocking or stimulating specific peptides or in-
jecting CB cells directly into the BM [9]. Other new
approaches for in vivo or ex vivo amplification of CB
cells have been developed [10,11]. Importantly, modi-
fiable factors related to donor CBU choice (such as cell
dose and degree of HLA incompatibility), and trans-
plantation procedures (such as conditioning regimen
Table 1. Experimental and Clinical Approaches to Increase
Number of Cord Blood Cells and Improve Engraftment after
UCB Transplantation
d Increase number of cells at cord blood collection
Banking cord blood units with greater volume and high
number of CD34+ cells
Perfusing the placental vessels after draining the blood from the cord
d Enhance homing of cord blood cells
Inhibiting the enzymatic activity of CD26/Dipeptidylpeptidase IV (DPPIV)
In vivo direct injection of cord blood cells into the iliac crest
(Phase II clinical trials)
d In vitro and in vivo expansion of cord blood cells
Using of SDF-1/CXCL12 associated to Diprotin A and/or other cytokines
Using Notch-ligand Delta 1 (Phase II clinical trials)
Using copper chelator tetraethylenepentamine (TEPA) (Phase II clinical
trials)
d Identification of modifiable prognostic factors for engraftment
Choosing the ‘‘best’’ cord blood unit based on cell dose, HLA, diagnosis,
screening for antibodies against HLA, quality of cord blood units (Table 2)
Modifying the conditioning regimen and GVHD prophylaxis
d Increase number of cells at infusion
Using double cord blood transplantation (on going prospective and
observational studies)
Using third party mobilized T cell-depleted haploidentical cells (Phase II
trials)
d Decreasing toxicity and shorten time of aplasia
Using RIC (on going prospective and observational studies)
d Coinfusion of cord blood cells with accessory cells
Using multipotent mesenchymal stromal cells (Phase I/ II trials)
GVHD indicates graft-versus-host disease; UBC, umbilical cord blood;
RIC, reduced intensity conditioning regimen.
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clinicians [12-22].
Other approaches aimed at decreasing toxicity and
shortening the time to engraftment after UCB trans-
plantation have shown encouraging results such as
the use of double unit CB transplants [23,24], the use
of reduced-intensity conditioning (RIC) regimens
[25,26], coinfusion with a haploidentical T cell-de-
pleted graft [27,28], or coinfusion with multipotent
mesenchymal stromal cells (MSCs) [29].
Table 1 lists experimental and clinical approaches
to circumvent the engraftment problem after UCBT.
Enhancing Collection, Homing, and Expansion
of CB Cells
Because of the limiting numbers of HSCs and
HPCs in banked CB, the means to: (1) enhance collec-
tion of CB cells [30], (2) enhance the homing and en-
graftment of HSCs /HPCs [31,32], and/or (3)
enhance the ex vivo or in vivo expansion of these cells
could greatly enhance the quality and usefulness of CB
cells for transplantation.
The CB cells collected for use in the first CB trans-
plants were composed of cells drained from the cord,
followed by retrieval of cells left in the placental blood
vessels to increase the numbers of cells for transplanta-
tion [12]. It is possible to substantially enhance the
numbers of HPC collected by perfusing the placental
vessels after draining the blood from the cord [30],
but the practicality of this method for banking remainsto be evaluated. If perfusion of the placenta after col-
lection of blood from the cord is untaken, it would
need to be done in selected collection centers with
well-trained personnel.
There have been a number of efforts to enhance the
homing and engraftment capability of HSCs and
HPCs. One such means is to inhibit the enzymatic ac-
tivity of CD26/Dipeptidylpeptidase IV (DPPIV) with
small peptides [31,32].CD26/DPPIV truncates and in-
activates the chemokine stromal cell derived factor-1
(SDF-1/CXCL12) that binds a receptor, CXCR4.
The SDF-1/CXCL12-CXCR4 axis is known to be im-
portant in the in vitro chemotaxis (directed cell move-
ment) and in vivo homing of mouse and human HSCs.
Not only is the truncated SDF-1/CXCL12 inactive,
but it also blocks the actions of the full-length active
form of SDF-1/CXCL12. This finding suggested that
a means to enhance SDF-1/CXCL12 activity by pre-
venting its truncation by CD26/DPPIV might
enhance the homing and engraftment of HSCs and
HPCs. Using small peptide inhibitors of CD26/
DPPIV such as Diprotin A or Val-Pyr, it was possible
to enhance the homing and engrafting capability of
mouse BMHSCs into lethally irradiated mice, and hu-
manCBHSCs into sublethally irradiatedNOD/SCID
mice [32]. SDF-1/CXCL12 also acts as a survival factor
for HSCs/HPCs, and most recently, SDF-1/CXCL12
was found to enhance the ex vivo expansion of CB
HPCs induced by the combination of stem cell factor,
Flt3-ligand, and thrombopoietin [30]. The addition of
Diprotin A to SDF-1/CXCL12 further enhanced ex
vivo output of HPCs (H.E. Broxmeyer, unpublished).
In addition to SDF-1/CXCL12 and a number of other
chemokines, there are other cytokines that have these
putative CD26/DPPIV truncation sites. Using Dipro-
tin A or CD262/2 cells, it was possible to enhance the
activity of selected members of the colony stimulating
factor (CSF) family in vitro. Moreover, it was deter-
mined that HPCs recovered much more rapidly and
at a higher level in CD262/2mice compared to control
mice after cytotoxic stress from low and higher, but not
lethal, doses of irradiation and from the chemothera-
peutic drugs, 5-flurouracil, and cyclophosphamide
(Cy; H.E. Broxmeyer, J. Hoggatt, S. Cooper, G.
Hangoc, L.M. Pelus, and T.B. Campbell, manuscript
in preparation). It is conceivable that pretreatment of
donor cells, and/or the recipientsmay enhance engraft-
ment of limiting numbers of HSC/HPC, such as are
present in CB collections.
Other mechanisms are under investigation with
the aim to improve ex vivo expansion of cord blood
cells. Phase I/II clinical trials have started to evaluate
safety and toxicity of infusing Notch-ligand Delta 1
or copper chelator tetraethylenepentamine (TEPA;
StemEx) to induce ex vivo expansion of CB progeni-
tors in patients with hematologic malignancies
[10,11]. Interestingly, Notch-ligand Delta 1 has also
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and differentiation [33].
Future efforts to expand HSC/HPC ex vivo and in
vivo, and to enhance the homing and engrafting capa-
bilities of CB cells will likely make use of more in depth
information on intracellular signaling molecules and
their networks involved in HSC and HPC functions,
including self-renewal, proliferative, survival, differen-
tiation, andmigration [34]. Further information on the
BM microenvironment and how HSC/HPC interact
with this microenvironment will permit the develop-
ment of more effective ways to achieve engraftment.Enhancing Homing Capacity with Direct
Intrabone Marrow Injection of CB Cells
The concept of enhancing homing capacity of CB
cells through the direct injection of CB cells into the
BM environment has led some investigators to apply
this approach clinically. In mice, it has been suggested
that intrabone infusion of CD341 CB cells confers an
engraftment advantage 15 times greater than after in-
travenous infusion, because cell loss during circulation
before homing is circumvented [35]. Recently, a phase
I/II study was performed to establish the safety and ef-
ficacy of a new administration route (intrabone) for CB
cells, measured by the donor-derived neutrophil and
platelet engraftment. Thirty-two patients had leuke-
mias, 14 with advanced disease. HLA-matching was
5/6, 4/6, and 3/6 for 9, 22, and 1 patient, respectively.
Most of the patients received a myeloablative (MA)
conditioning regimen associated with antithymocyte
globulin (ATG) and only 2 patients recived an RIC
regimen prior to UCB transplantation. CB cells
were concentrated in 4 5-mL syringes, and were in-
fused in the superior-posterior iliac crest under rapid
general anaesthesia. Median transplanted cell dose
was 2.6  107/kg. No complications occurred during
or after the intrabone infusion of cells. Median time
to recovery of neutrophils was 23 days (range: 14-44)
and median time to recovery of platelets was 36 days
(range: 16-64). All patients were fully chimeric from
30 days after transplantation to the last follow-up visit,
suggesting early complete donor engraftment. No pa-
tient developed grade III-IV acute graft-versus-host
disease (aGVHD). More recently, in a preliminary
matched pair analysis comparing patients transplanted
with CB injected intravenously (IVCB) versus CB in-
jected directly into the BM (IBCB) of the iliac crest,
IBCB patients (n 5 50) were matched with 88 IVCB
recipients. Cumulative incidence (CI) of neutrophil re-
covery was 70%6 5% in IVCB recipients versus 80%
6 6% in the IBCB group (P5 .27). However, patients
receiving IBCB had a higher CI of platelet recovery at
day 60 (82% 6 5%) compared to the IVCB group
(40% 6 5%; P\ .0001). Strikingly, the incidence of
aGVHD grade II-IV was 12% in the IBCB groupcompared to 38% in the IVCB group (P 5 .0001)
and the incidence of grade III-IV aGVHD was 2%
compared to 18% (P\ .001), respectively. Overall sur-
vival (OS) at 1 year was 67% 6 7% compared to 43%
6 5% (P5 .07), respectively. In summary, injection of
CB cells into the BM appears to significantly reduce
the problem of delayed platelet recovery observed
after IVCB. The reduced incidence and severity of
aGVHD observed in IBCB patients is intriguing and
promising [9]. This procedure has been adopted in
some European transplant centers in phase I/II
clinical trials, in which that a collected nucleated cell
dose is found cell dose between 1.5 and 2.5  107/kg
with the aim to avoid performing double cord blood
transplants.Risk Factors That Affect Engraftment: CB Graft
and Transplantation-Related Factors
Interactions of cell dose, HLA, and diagnosis
As cell dose andHLA disparities are important and
independent prognostic factors, it has been suggested
that both interact mutually on engraftment and other
outcomes. Thus, a higher cell dose in the graft should
partially overcome the negative impact of HLA mis-
match for each level of HLA disparity. It has been
speculated that for each HLA disparity, the nucleated
cell dose should be increased by 1.5  107/kg. How-
ever, as the hypothesis has not been fully tested and
the recommendation at the present time is unvalidated,
this approach has yet to be adopted. Using this algo-
rithm many patients will not find a suitable single
CBU and will need a double CB transplant. The Euro-
cord group and others have made some recommenda-
tions regarding criteria for donor choice. A strategy for
CBU choice based on cell dose, HLAmatch, and diag-
nosis is listed in Table 2 [36].
The following considerations should be taken into
account when choosing a CBU to improve engraft-
ment:
1. Cell content marker: the CD341 cell content at the
time of freezing is considered a better marker for
HSC and HPC than either the total nucleated cell
(TNC) at the time of freezing or the CD341 cell
content after thawing. Colony-forming units gran-
ulocyte-macrophage (CFU-GM) in the CB graft
represents clonogenic potential. However, because
of logistic, technical, and economic issues, the use
of this cell marker is difficult to apply routinely as
a surrogate marker for CBU choice.
2. HLA allelic matching: high-resolution typing for
HLA-A, -B, and -DRB1 was associated with
decreased incidence of aGVHD and a trend toward
improved survival, but had no impact on neutrophil
or platelet engraftment after UCB transplantation
in children [20]. To determine the real value of allele
Table 2. Considerations for Cord Blood Unit Choice
1) At selection, diagnosis and presence of patient HLA antibodies against the HLA antigens [37] of the cord blood unit should be considered.
HLA compatibility appears to be more important for patients with nonmalignant disorders than for those with malignant disorders [1].
2) If the below criteria for a single UCB transplantation is not achieved, a double cord blood transplantation should be considered in prospective trials.
HLA definition: based on HLA antigenic for -A and -B and allelic typing for HLA-DRB1. Avoid cord blood units with 3 or 4 HLA disparities.
Recommendations for HLA and cell dose (speculative)
1) Cord blood unit with 6/6 or 5/6 HLA match. HLA-A or HLA-B mismatches are preferable to DRB1 mismatches. HLA-DRB1 mismatch could
probably lead to high graft-versus-leukemia (GVL) effect in patients transplanted in nonremission (based on Eurocord unpublished and preliminary data).
Malignant disorders:
Nucleated cell dose: at freezing, minimum cell dose 2.5 to 3.0  107/kg after thawing, minimum 2.0 to 2.5  107/kg*
(this recommendation is partially based on Eurocord, New York Placental Blood Center and CIBMTR data) [6,13,15].
*If the nucleated cell dose infused is <1.0  107/kg, an immediate second transplant should be considered because the early mortality associated to this
cell dose is approximately 70%. If the nucleated cell dose infused is between 1.0 to 2.0  107/kg, we recommend that the number of CD34+ cells
and CFU-GM should be taken into consideration to predict the probability of neutrophil recovery and to consider a second transplant. If both
cell doses are lower than recommended, a bone marrow aspirate and chimerism analysis should be performed between day +20 and day +28 to
confirm the absence of engraftment and to indicate a second transplant.
CD34+ cell dose: at freezing or after thawing, approximately 1.2 to 1.7  105/kg (this recommendation is based on data published [13,16,17]
Colony forming units assay: when available, the cord blood bank should inform the value and technique of CFU-GM counting.
Nonmalignant disorders: same total and CD34+ cell dose requested, but HLA match should always be selected and avoid DRB1 mismatching.
Cord blood unit with 4/6 HLA match (this recommendation is not proved by retrospective studies, but based on transplant algorithm for cord
blood unit selection and unpublished Eurocord data) HLA-A or HLA-B mismatches are better than HLA-DRB1 mismatches. HLA-DRB1
mismatch could probably lead to high GVL effect in advanced phase of the diseases (based on Eurocord unpublished and preliminary data).
Malignant disorders
Nucleated cell dose: at freezing, minimum cell dose 3.5  107/kg after thawing, minimum 3.0  107/kg*
CD34+ cell dose: at freezing or after thawing, approximately >1.7  105/kg
Colony forming units assay: when available, the cord blood bank should provide the CFU-GM count and the method used to determine this result.
Nonmalignant disorders (based on unpublished Eurocord study)
Nucleated cell dose: at freezing, minimum cell dose 4 to 5  107/kg after thawing, minimum 3.5  107/kg*
CD34+ cell dose: no available data, but should be higher than 2 to 2.5  105/kg
Colony forming units assay: when available, the cord blood bank should provide the CFU-GM count and the method used to determine this result.
2) CB units with 3/6 HLA match: should be avoided, but in extremely severe cases for patients with malignant disorders should be considered with high nucleated
cell dose. Not recommended for patients with nonmalignant disorders.
Other considerations:
If a number of cord blood units are available that fit the above criteria, the following should to be taken into consideration:
1) Accredited Cord blood bank and location
2) ABO compatibility
3) Allele HLA typing of HLA-A and -B
UCB indicates umbilical cord blood; CIBMTR, Center for International Blood and Marrow Transplant Research; CFU-GM, Colony-forming units gran-
ulocyte-macrophage.
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tient-donor pairs will be needed to reach statistical
significance.
3. Patients’ pretransplant anti-HLA antibodies: pre-
formed anti-HLA antibodies also seem to have an
impact on neutrophil and platelet engraftment after
UCB transplantation. Because most UCB trans-
plants are HLA mismatched, the presence of
anti-HLA antibodies in the patient against HLA
epitopes of the CBU should be investigated prior
to transplant [37].
4. Unrelated donor CB banks—economic and quality
aspects: economic concerns (such as costs of the
price unit in double CB transplantation), the dis-
tance of CB banks, and, more importantly, the qual-
ity of the CBU are considerations when selecting
a CBU. However, very few studies have analyzed
the impact of CB banking procedures (such as pre-
freezing manipulation, volume reduction, viability
of CB cells after thawing, methods of cryopreserva-
tion and thawing, etc.) on engraftment and other
outcomes after UCB transplantation.Transplantation related factors: conditioning
regimen and GVHD prophylaxis
Factors related to the technique of transplantation,
such as conditioning regimen and GVHD prophylaxis
may also be associated with more rapid engraftment.
In a recent Eurocord study, the use of fludarabine
(Flu) inMA conditioning regimens was associated with
improved neutrophil and platelet recovery in adult
UCB transplantation recipients receiving a lower
TNC dose [21]. In this study, the role of antithymo-
cyte globulin (ATG)/antilymphocyte globulin (ALG)
could not be evaluated as it was used in almost all
UCB transplantation performed. Use of Flu in the
preparative regimen has also been associated with im-
proved engraftment independent of cell dose andHLA
in UCB transplantation for patients with Fanconi
anemia (FA) [38]. Conversely, the use of methotrexate
(MTX) containing regimens for GVHD prophylaxis
has been associated with delayed engraftment and in-
creased risk of graft failure in patients with hemoglo-
binopathies transplanted with an HLA identical
sibling CBU [22]. However, its use elsewhere in
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the United States, the most common regimen is calci-
neurin inhibitor-based GVHD prophylaxis alone or in
combination with steroids or mycophenolate mofetil
(MMF). However, Japanese transplant centers have
shown interesting results with calcineurin inhibitors
in combination with low-dose MTX [39,40]. Only
prospective studies may establish the role of MTX in
GVHD prophylaxis for UCB transplantation.
New Approaches to Improve Engraftment and
Decrease Early Transplantation Mortality
Because cell dose is considered to be a critical
determinant of outcomes in UCBT, the Minneapolis
group has demonstrated that transplantation of 2 par-
tiallyHLAmatched cord unitsmay overcome the prob-
lem of cell dose andmake the transplantation of heavier
adult patients feasible. This strategy has led to an in-
creased number of adult patients receiving unrelated
cord blood transplantation. Results with double cord
blood transplantation support the safety of the proce-
dure [23,24]. Chimerism data from these studies reveal
that typically only 1 cord blood engrafts. Despite the
fact that double CB transplant recipients are heavier
than patients receiving a single unit, cumulative inci-
dence of neutrophil recovery does not differ statistically
between the 2 groups. This observation suggests a
‘‘booster’’ effect from the nonengrafting unit. Recent
data from the Minnesota group suggests that double
UCB transplantation is associated with a higher inci-
dence of aGVHD, when recipients of single (n 5 210)
versus double (n 5 169) UCB transplantation have
been compared, but without an increase in nonrelapse
mortality (NRM). Interestingly, analysis of 177 patients
with acute leukemiawherein47%ofpatientsweregiven
single CBUs and 53% given 2 partially HLA-matched
units, relapse was significantly lower for early stage
(CR1-2) patients who received 2UCBunits, suggesting
a higher graft-versus-leukemia (GVL) effect. Leuke-
mia-free survival (LFS) was 40% and 51% for single
and double unit recipients, respectively (P5 .35) [41].
These results may have important scientific impli-
cations in terms of understanding the immunology of
cord blood transplantation, the nature of the HSC
niche and how modulation of this niche may impact
upon transplant outcome.
RIC Regimen Prior to Single or Double UCB
Transplantation from Unrelated Donors in
Adults
Most studies have tested UCB transplantation in
the setting of myeloablative conditioning. An RIC
regimen before UCB transplantation has been increas-
ingly used to decrease toxicity, shorten the duration of
aplasia, and extend the availability of CB transplanta-
tion to the elderly or patients who are not eligiblefor MA conditioning. TheMinnesota group has evalu-
ated the efficacy of UCB in the setting of a nonmyeloa-
blative regimen consisting of Flu, Cy, and a single
fraction of total body irradiation (TBI) (200 cGy)
with cyclosporine (CsA) andMMFfor posttransplanta-
tion immunoprophylaxis. The target cell dose for the
UCB graft was 3.0  107 nucleated cells/kg, resulting
in the selection of a second partially HLA-matched
UCB unit in 85% of patients [24]. One hundred ten
patients with hematologic diseaseswere enrolled.Neu-
trophil recovery was achieved in 92% at a median of 12
days. One cord blood unit predominated engraftment
and none of the following factors were predictive of
which unit eventually dominated: total nucleated,
CD341, and CD31 cell doses; HLA matching; nucle-
ated cell viability; ABO typing; sex match; or order of
unit infusion. Treatment-related mortality (TRM)
was 26% at 3 years. Survival and event-free survival
(EFS) at 3 years were 45% and 38%, respectively.
More recently, the Societe Franc¸aise de Greffe de
Moelle-TherapieCellulaire (SFGM-TC) in collabora-
tion with Eurocord reported results of 155 consecutive
UCB transplantations performed using an RIC regi-
men with a median follow-up of 18 months (range:
2-56) [42]. The median age was 47 years (18-69 years).
Sixty-nine patients had myeloid and 22 lymphogenous
acute leukemia (59%), 33 patients had other lymphoid
malignancies, 18 had myelodysplastic syndrome
(MDS), 8 myeloma, and 5 chronic myelogenous leuke-
mia (CML). At time of transplantation, 20%of patients
had active disease. Conditioning regimens consisted of
Flu 150 to 200 mg/m2, Cy 50 mg/kg and TBI 2 Gy.
Two CBUs were infused in 59 (38%) patients. In the
case of double UCB transplantation, the classification
of HLA and ABO took into consideration the unit
with the highest degree of disparity. Therefore, HLA
identity was 6/6 in 5 patients, 5/6 in 28 patients, 4/6
in 93 and #3/6 in 8; 42 patients had a minor and 65
a major ABO incompatibility. The number of total nu-
cleated cells and CD341 cells infused were 3.1  107/
kg and 1.2  105/kg, respectively. The amounts were
2.8  107/kg and 1.4  105/kg for the single unit and
3.6  107/kg and 1.6  105/kg in double unit UCB
transplantations, respectively. CsA and MMF were
used for GVHD prophylaxis. Cumulative incidence
of neutrophil engraftment at day 160 was 80% 6
3%, with a median time to achieve neutrophils .0.5/
L of 20 days; autologous recovery was seen in 14% of
the patients. In multivariate analysis, factors indepen-
dently associated with better neutrophil recovery
were CD34 cell dose (.1.2  105/kg) (hazard ratio
[HR] 1.51, P 5 .04), HLA compatibility (0-1 versus
2-3) (HR 1.5, P 5 .05) and previous autograft (HR
1.8,P\.01). Cumulative incidence of nonrelapsemor-
tality (NRM) was 18% 6 3% at 18 months. The esti-
mated probability of OS and DFS at 18 months was
62% 6 5% and 51% 6 4%, respectively.
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ity of RIC-UCB transplantation and reported encour-
aging results with this approach. Despite reducing the
duration of aplasia, cumulative incidence of engraft-
ment remains between 80% and 90%. Once again
HLA disparity and cell dose played an important role
and myeloid engraftment was achieved in 94% when
patients received a well HLA-matched (6/6 or 5/6)
CBUs with a higher CD34 cell dose (42).
Use of Accessory Cells to Improve Engraftment
Cotransplantation of an UCB unit with highly
purified CD341 cells from haploidentical
family donors
Phase I-II clinical trials using accessory popula-
tion(s) to enhance engraftment have been published,
with interesting results. The Spanish group developed
a strategy of UCB transplantation with coinfusion of
a limited number of highly purified mobilized HSC
(MHSC) from a human leukocyte antigen (HLA) unre-
stricted third party donor (TPD). Short posttransplant
periods of neutropenia were generally observed in
adults with hematologic disorders receiving UCBT
with a relatively low cell content and 0-3 HLA
mismatches after MA conditioning. This shortened
neutropenic phase was was because of an early and ini-
tially predominant engraftment of the TPD-MHSC.
After a variable period of double complete TPD 1
UCB chimerism, final full UCB chimerism was
achieved (cumulative incidence .90%) within 100
days. Early recovery of the circulating neutrophils
resulting from the ‘‘bridge transplant’’ of the TPD-
MHSC reduced the incidence of serious neutropenia-
related infections, also facilitating the use of drugs
with myelosuppressive side effects to combat other
infections. The observed incidence of GVHD and re-
lapses was low, with OS and DFS curves comparable
to thoseofHLA identical sibling transplants [27,28,43].
Cotransplantation of an UCB unit with
haploidentical parenteral multipotent mesenchymal
stromal cells
Mcmillan et al. [29] have reported an attempt to
speed hematopoietic recovery in a single-institution
phase I-II clinical trial in which ex vivo culture-ex-
panded multipotent MSCs from haploidentical paren-
tal donors were infused at the time of UCB
transplantation. Fifteen pediatric patients with high-
risk acute leukemia were enrolled. Eight patients re-
ceived MSCs on day 0, with 3 patients having a second
dose infused on day 21. No serious adverse events were
observed with any MSC infusion. All 8 evaluable pa-
tients achieved neutrophil engraftment at a median of
19 days. Probability of platelet engraftment was 75%,
at a median of 53 days. With a median follow-up of
6.8 years, 5 patients remain alive and disease free. Ina another pilot study [44] the Madrid group have used
ex vivo-expanded BM MSC from parental donors
that were infused at the time of the transplantation or
the in case of refractory aGVHD. Nine patients re-
ceivedMSC immediately after CB andTPDhighly pu-
rified mobilized HSC. Neither immediate adverse
effects nor significant differences in CB engraftment
or aGVHD development were observed. Four patients
developed grade II aGVHD, refractory to steroids in 2.
These reached complete remission (CR) after thera-
peutic infusions of MSC.
The results of both pilot studies show that infusion
of ex vivo culture-expanded haploidentical MSCs into
unrelated UCB transplantation recipients can be per-
formed safely. Further studies may investigate the
role of coinfusion of MSC to improve engraftment
after UCB transplantation.CONCLUSION
Engraftment and other outcomes after UCBT are
improving in the recent years, mainly because of better
donor choices (cell dose and HLAmatching), early pa-
tients referral for transplantation, improvement in
supportive care, and greater center experience. Other
approaches that improve engraftment after UCBT
are being currently developed with very encouraging
results. Those approaches may greatly increase the
clinical use of cord blood cells for transplantation.ACKNOWLEDGMENTS
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